Dianthus Therapeutics (NASDAQ:DNTH) Hits New 12-Month High – Here’s Why

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) hit a new 52-week high on Saturday . The stock traded as high as $41.15 and last traded at $40.85, with a volume of 1574910 shares traded. The stock had previously closed at $35.50.

Analyst Ratings Changes

A number of brokerages have weighed in on DNTH. Robert W. Baird lifted their price objective on Dianthus Therapeutics from $50.00 to $67.00 and gave the company an “outperform” rating in a report on Tuesday, September 9th. HC Wainwright boosted their price objective on Dianthus Therapeutics from $40.00 to $47.00 and gave the company a “buy” rating in a report on Monday, November 10th. Stifel Nicolaus boosted their price target on shares of Dianthus Therapeutics from $52.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Truist Financial initiated coverage on Dianthus Therapeutics in a research note on Tuesday, October 14th. They issued a “buy” rating and a $56.00 price target for the company. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $63.00 target price (up from $56.00) on shares of Dianthus Therapeutics in a research report on Tuesday, September 9th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Dianthus Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $63.43.

Dianthus Therapeutics Stock Up 15.1%

The company has a market cap of $1.75 billion, a PE ratio of -11.74 and a beta of 1.56. The stock has a 50-day moving average of $35.94 and a 200-day moving average of $25.67.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Wednesday, November 5th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.11). The business had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.58 million. Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%. Research analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Ryan Savitz sold 20,000 shares of Dianthus Therapeutics stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $35.00, for a total transaction of $700,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Simrat Randhawa sold 109,031 shares of the company’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $38.14, for a total value of $4,158,442.34. Following the transaction, the executive vice president directly owned 4,000 shares in the company, valued at $152,560. This represents a 96.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 216,538 shares of company stock valued at $8,079,575 in the last ninety days. 16.56% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Raymond James Financial Inc. boosted its position in shares of Dianthus Therapeutics by 686.4% during the third quarter. Raymond James Financial Inc. now owns 11,245 shares of the company’s stock valued at $442,000 after buying an additional 9,815 shares during the last quarter. Acuta Capital Partners LLC bought a new stake in shares of Dianthus Therapeutics during the 3rd quarter valued at about $984,000. Balyasny Asset Management L.P. purchased a new position in shares of Dianthus Therapeutics in the third quarter valued at about $17,460,000. Longaeva Partners L.P. bought a new stake in shares of Dianthus Therapeutics in the 3rd quarter valued at approximately $984,000. Finally, Brooklyn Investment Group bought a new stake in Dianthus Therapeutics during the 3rd quarter valued at $262,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.